1. Home
  2. PBYI vs ULBI Comparison

PBYI vs ULBI Comparison

Compare PBYI & ULBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBYI
  • ULBI
  • Stock Information
  • Founded
  • PBYI 2010
  • ULBI 1990
  • Country
  • PBYI United States
  • ULBI United States
  • Employees
  • PBYI N/A
  • ULBI N/A
  • Industry
  • PBYI Biotechnology: Pharmaceutical Preparations
  • ULBI Industrial Machinery/Components
  • Sector
  • PBYI Health Care
  • ULBI Miscellaneous
  • Exchange
  • PBYI Nasdaq
  • ULBI Nasdaq
  • Market Cap
  • PBYI 153.2M
  • ULBI 158.1M
  • IPO Year
  • PBYI N/A
  • ULBI 1992
  • Fundamental
  • Price
  • PBYI $3.09
  • ULBI $7.76
  • Analyst Decision
  • PBYI Strong Buy
  • ULBI Strong Buy
  • Analyst Count
  • PBYI 1
  • ULBI 1
  • Target Price
  • PBYI $7.00
  • ULBI $14.00
  • AVG Volume (30 Days)
  • PBYI 754.5K
  • ULBI 54.3K
  • Earning Date
  • PBYI 02-27-2025
  • ULBI 02-13-2025
  • Dividend Yield
  • PBYI N/A
  • ULBI N/A
  • EPS Growth
  • PBYI 492.79
  • ULBI 115.20
  • EPS
  • PBYI 0.47
  • ULBI 0.54
  • Revenue
  • PBYI $243,569,000.00
  • ULBI $165,152,000.00
  • Revenue This Year
  • PBYI N/A
  • ULBI $3.26
  • Revenue Next Year
  • PBYI N/A
  • ULBI $36.05
  • P/E Ratio
  • PBYI $6.63
  • ULBI $14.23
  • Revenue Growth
  • PBYI 6.30
  • ULBI 9.95
  • 52 Week Low
  • PBYI $2.23
  • ULBI $6.63
  • 52 Week High
  • PBYI $7.73
  • ULBI $13.39
  • Technical
  • Relative Strength Index (RSI)
  • PBYI 49.17
  • ULBI 55.36
  • Support Level
  • PBYI $2.92
  • ULBI $7.15
  • Resistance Level
  • PBYI $4.06
  • ULBI $7.83
  • Average True Range (ATR)
  • PBYI 0.29
  • ULBI 0.28
  • MACD
  • PBYI 0.01
  • ULBI 0.05
  • Stochastic Oscillator
  • PBYI 27.07
  • ULBI 86.05

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

About ULBI Ultralife Corporation

Ultralife Corp provides products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government and defense, medical, safety and security, energy, and industrial sectors. The company designs, manufactures, installs, and maintains power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom-engineered systems. The company's segments include Battery and Energy Products, and Communications Systems. It generates maximum revenue from the Battery and Energy Products segment, and from the U.S. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, and various other non-rechargeable batteries.

Share on Social Networks: